The capsule endoscopy market size is expected to reach $2.15 billion by 2033, as the high incidence of gastrointestinal diseases drives demand for non-invasive diagnostics.

Introduction

As the global incidence of gastrointestinal diseases continues to rise, an examination method that requires no intubation—only the swallowing of a "capsule"—is reshaping the landscape of gastroenterological diagnosis. According to the latest research released by Growth Market Reports, the global capsule endoscopy system market reached USD 1.09 billion in 2024 and is expected to double to USD 2.15 billion by 2033, with a compound annual growth rate (CAGR) of 8.2%. Behind this growth lies the urgent demand from healthcare systems for non-invasive, early diagnostic tools, as well as the empowerment of imaging diagnostics by technologies such as artificial intelligence.

Industry Background

Although traditional gastrointestinal endoscopy is accurate, it is often accompanied by discomfort, requires sedatives, and carries a risk of perforation. Capsule endoscopy involves the patient swallowing a capsule equipped with a miniature camera, which continuously captures images of the digestive tract and transmits them to an external recorder, without the need for intubation or sedation, significantly improving patient compliance. Currently, this technology is primarily used for detecting Crohn's disease, colorectal cancer, and obscure gastrointestinal bleeding.

In the Asia-Pacific region, the burden of gastrointestinal diseases is particularly heavy. Data from the World Health Organization shows that colorectal cancer has become the third most common cancer worldwide, and early screening can significantly reduce mortality. On the regulatory front, healthcare systems in various countries are gradually including capsule endoscopy in their reimbursement schemes. For example, Japan and South Korea have already adopted it as a routine option for gastrointestinal screening. This provides policy support for market expansion.

Key Advances

In recent years, technological iterations in capsule endoscopy have focused mainly on three areas: imaging quality, battery life, and real-time transmission. Manufacturers have introduced higher-resolution cameras and longer-lasting batteries, enabling capsules to work longer in the intestinal tract and capture clearer images. At the same time, real-time image transmission technology allows doctors to dynamically monitor the examination process rather than only reviewing it afterward.

AI-assisted analysis is currently the most notable breakthrough. Each capsule endoscopy examination can generate tens of thousands of images, and manual interpretation is time-consuming and prone to missing lesions. Several companies have developed deep learning-based algorithms capable of automatically identifying abnormalities such as bleeding, polyps, and inflammation, with sensitivity and specificity exceeding 90%. For example, the RAPID AI system from Israeli company Given Imaging (now part of Medtronic) has been deployed in multiple clinical centers, reducing reading time by over 40%.

Market Impact

The fast-growing market has attracted numerous players. In addition to traditional imaging giants like Medtronic, Olympus, and Fujifilm, startups from China and Israel are also launching differentiated products. For instance, Shenzhen-based Ankon Technologies has received NMPA approval in China. Its magnetically controlled capsule gastroscopy system can actively control the capsule's movement through an external magnetic field, enabling precise stomach examinations.For medical institutions, capsule endoscopy reduces reliance on endoscopists and frees up endoscopy room resources. Both the Mayo Clinic and Cleveland Clinic in the United States have established capsule endoscopy screening workflows, performing over 10,000 cases annually. In Asia, the National University Hospital of Singapore and the University of Tokyo Hospital in Japan use it for monitoring inflammatory bowel disease, with patient satisfaction scores significantly higher than traditional endoscopy.

Challenges and Risks

Despite its promising prospects, capsule endoscopy remains constrained by high costs. A single examination typically costs between $500 and $2,000, far exceeding traditional gastroscopy (about $200–$500), making it particularly difficult to popularize in developing countries. Moreover, capsule endoscopy only provides diagnostic functions and cannot perform tissue biopsy or treatment—meaning that after detecting abnormalities, traditional endoscopy is still needed for secondary intervention, increasing overall medical costs and time.

Another bottleneck is image data interpretation. Even with AI assistance, capsule endoscopy requires trained physicians to review a large number of images. A report by Growth Market Reports notes that "the need for well-trained professionals to effectively interpret vast amounts of image data" is one of the limiting factors. Currently, there is a shortage of gastrointestinal endoscopists worldwide, especially in primary care institutions, and this talent gap may limit the promotion of capsule endoscopy.

Future Outlook

Over the next 3–5 years, capsule endoscopy will evolve toward intelligence, therapeutic capabilities, and lower costs. In terms of AI, new-generation algorithms can not only detect lesions but also predict lesion characteristics (e.g., benign vs. malignant), and even mark precise locations with millimeter-level positioning information. Therapeutic capsules (e.g., drug release, tissue sampling) have made progress in animal experiments and are expected to enter clinical use around 2030.

On the regulatory front, the U.S. FDA and the EU CE have included capsule endoscopy in the priority review channel for innovative medical devices. China's National Medical Products Administration has also issued review guidelines for AI-assisted diagnostic software. Capital is flowing in: in the first half of 2024, global financing in the capsule endoscopy field exceeded $300 million, with AI image analysis companies accounting for half.

Conclusion

The growth trajectory of the capsule endoscopy market clearly points to a future of non-invasive, intelligent diagnostics. Against the backdrop of a continuously increasing burden of gastrointestinal diseases, this technology is transforming from an auxiliary tool into a first-line screening method. With AI integration, cost reduction, and breakthroughs in therapeutic functions, it has the potential to redefine the standard procedure of gastroenterology—not only for diagnosis but also as a bridge connecting screening and treatment. Any investor or practitioner concerned with digital health, medical devices, and AI healthcare should pay close attention to this track.